NASDAQ:ENTA

Enanta Pharmaceuticals Q4 2026 Earnings Results & Report

Enanta Pharmaceuticals logo
$8.36 -0.33 (-3.74%)
As of 02:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Enanta Pharmaceuticals missed analyst expectations on both earnings and revenue in its Q4 2026 results, released November 18, 2026. The company reported EPS of -$0.81 versus the -$0.7240 consensus estimate, while revenue of $12.87 million fell short of the $14.62 million estimate by $1.75 million.

Earnings Announcement Details

Quarter
Q4 2026
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET

Enanta Pharmaceuticals EPS Results

Actual EPS
-$0.81
Consensus EPS
-$0.7240
Beat/Miss
Missed by -$0.0860
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Enanta Pharmaceuticals Revenue Results

Actual Revenue
$12.87 million
Expected Revenue
$14.62 million
Beat/Miss
Missed by -$1.75 million
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Q4 2026 Earnings FAQ

Enanta Pharmaceuticals (NASDAQ:ENTA) reported earnings of -$0.81 per share for Q4 2026, missing the consensus estimate of -$0.7240. The report was announced on Wednesday, November 18, 2026.

Enanta Pharmaceuticals reported revenue of $12.87 million for Q4 2026, against a consensus estimate of $14.62 million.

Enanta Pharmaceuticals Earnings Headlines

A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Enanta Pharmaceuticals Fiscal Q4 Loss Narrows, Revenue Falls
Enanta Pharmaceuticals (ENTA) Expected to Release Quarterly Earnings on Monday
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA) is a biotechnology company based in Watertown, Massachusetts, that discovers and develops small-molecule medicines. Its research has focused on infectious diseases and inflammatory conditions, including respiratory syncytial virus (RSV), hepatitis B and immunology.

Enanta’s work with AbbVie contributed to the discovery of glecaprevir, an antiviral used with pibrentasvir in the hepatitis C treatment Mavyret. The collaboration reflects the company’s history of applying its drug-discovery expertise to antiviral therapies.

The company continues to advance a pipeline of investigational medicines, including programs targeting RSV and other viral diseases, as well as inflammatory disorders. These candidates remain subject to clinical development and regulatory review.

View Enanta Pharmaceuticals Profile